OBJECTIVE To evaluate organ dose and total effective dose of whole-body low-dose CT (WBLDCT) performed on different CT-scanner models in patients with multiple myeloma (MM) and to compare it to the effective dose of radiographic skeletal survey and representative diagnostic CTs. MATERIAL AND METHODS We retrospectively analyzed data from 228 patients (47.4% females, mean age 67.9 ± 10.4 years, mean weight 81.8 ± 22.4 kg) who underwent WBLDCT for the work-up or surveillance of MM. Patients were scanned using one of six multi-detector CT-scanners. Organ doses and total effective doses per scan were calculated using a commercially available dose-management platform (Radimetrics, Bayer Healthcare, Leverkusen, Germany). The median effective dose was compared to radiographic skeletal survey and representative diagnostic CTs. RESULTS The mean effective dose of our WBLDCT-protocol was 4.82 mSv. A significantly higher effective dose was observed in females compared to males (4.95 vs. 4.70 mSv, P = 0.002). Mean organ dose ranged from 3.72 mSv (esophagus) to 13.09 mSv (skeleton). Mean effective dose varied amongst different CT-scanners (range 4.34-8.37 mSv). The median effective dose of WBLDCT was more than twice the dose of a skeletal survey (4.82 vs. 2.04 mSv), 23% higher than a diagnostic contrast-enhanced chest CT (3.9 mSv), 46% lower than a diagnostic contrast-enhanced abdomen/pelvis CT (9.0 mSv), and 45% lower than a lumbar spine CT (8.7 mSv). CONCLUSIONS WBLDCT in MM has a higher effective dose than a radiographic skeletal survey, but a lower effective dose than diagnostic CTs of lumbar spine, abdomen and pelvis. This underlines the broad applicability of WBLDCT in the management of MM patients.

中文翻译：

---

多发性骨髓瘤患者的全身CT器官剂量和总有效剂量。

目的评估多发性骨髓瘤（MM）患者在不同CT扫描仪模型上进行的全身低剂量CT（WBLDCT）的器官剂量和总有效剂量，并将其与放射线骨架检查和代表性诊断的有效剂量进行比较CT。材料和方法我们回顾性分析了WBLDCT进行MM检查或监测的228例患者（女性47.4％，平均年龄67.9±10.4岁，平均体重81.8±22.4 kg）的数据。使用六台多探测器CT扫描仪之一对患者进行了扫描。使用市售的剂量管理平台（Radimetrics，Bayer Healthcare，Leverkusen，德国）计算每次扫描的器官剂量和总有效剂量。将中位有效剂量与影像学骨骼检查和代表性诊断性CT进行比较。结果我们的WBLDCT协议的平均有效剂量为4.82 mSv。与男性相比，女性的有效剂量明显更高（4.95 vs.4.70 mSv，P = 0.002）。平均器官剂量范围为3.72 mSv（食道）至13.09 mSv（骨骼）。平均有效剂量在不同的CT扫描仪之间有所不同（范围为4.34-8.37 mSv）。WBLDCT的中位有效剂量是骨骼检查剂量的两倍以上（4.82 vs. 2.04 mSv），比诊断性对比增强胸部CT（3.9 mSv）高23％，比诊断性对比增强腹部低46％。 /骨盆CT（9.0 mSv），比腰椎CT（8.7 mSv）低45％。结论MMLD中WBLDCT的有效剂量高于放射学骨骼检查，但比腰椎，腹部和骨盆的诊断性CT低。